# ABVX catalysts: Abivax S.A. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/abvx/catalysts

> Abivax S.A. (ABVX) has 4 upcoming catalysts. The next is the obefazimod primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Abivax S.A. |
| Ticker | ABVX (Nasdaq) |
| SEC CIK | 1956827 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/abvx |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2024 | [Obefazimod trial start](https://sec-api.dev/pdufa/obefazimod) | ABVX | Crohn's disease | completed | "We have also initiated a Phase 2b clinical trial of obefazimod in patients with Crohns disease (CD), with our first patient enrolled in October 2024, and we are evaluating other potential inflammatory indications." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1956827/000119312525164456/d945355d424b5.htm)) |
| June 24, 2025 | [Obefazimod primary completion](https://sec-api.dev/pdufa/obefazimod) | ABVX | Ulcerative Colitis | completed | "NCT05507203 (ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-24 (ACTUAL); Lead Sponsor Abivax S.A.; Results First Posted 2026-09-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05507203)) |
| June 24, 2025 | [Obefazimod primary completion](https://sec-api.dev/pdufa/obefazimod) | ABVX | Ulcerative Colitis | completed | "NCT05507216 (ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-24 (ACTUAL); Lead Sponsor Abivax S.A.; Results First Posted 2026-09-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05507216)) |
| Q3 2025 | [Obefazimod topline data readout](https://sec-api.dev/pdufa/obefazimod) | ABVX |  | scheduled | "We remain fully committed to advancing this pivotal program: we expect to report top-line induction results in Q3 2025, followed by comprehensive long-term maintenance data in Q2 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1956827/000195682725000016/exhibit991-abtectfullenrol.htm)) |
| Q3 2025 | [Abivax S.A. topline data readout](https://sec-api.dev/companies/abvx/catalysts) | ABVX |  | scheduled | "The Company confirmed that it remains on track to complete induction trials enrollment in the second quarter of 2025, with top-line induction data expected in the third quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1956827/000119312525089339/d919877dex991.htm)) |
| Q3 2025 | [Abivax S.A. topline data readout](https://sec-api.dev/companies/abvx/catalysts) | ABVX |  | scheduled | "Phase 3 ABTECT induction trials remain on track: enrollment completion expected in Q2 2025, with top-line induction results expected in Q3 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1956827/000119312525089339/d919877dex991.htm)) |
| July 22, 2025 | [Obefazimod topline data readout](https://sec-api.dev/pdufa/obefazimod) | ABVX |  | completed, positive | "Paris: FR0012333284  ABVX / Nasdaq: ABVX) (Abivax or the Company), a clinical-stage biotechnology company focused on developing therapeutics that harness the bodys natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced positive topline results from its Phase 3 ABTECT-1 (Study 105) and ABTECT-2 (Study 106) 8-week induction trials evaluating its oral, first-in-class miR-124 enhancer, obefazimod (ABX464), in adult patients with moderately to severely active ulcerative colitis (UC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1956827/000119312525162671/d56921dex991.htm)) |
| Q4 2025 | [Obefazimod topline data readout](https://sec-api.dev/pdufa/obefazimod) | ABVX |  | scheduled | "Under these assumptions and based on the Group's current clinical and operational plans, the Group would have sufficient funds to finance its operations in the fourth quarter of 2025, i.e. through the announcement of its top-line data from the Phase 3 ABTECT-1 and ABTECT-2 induction trials for" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1956827/000195682725000010/abvx-20241231.htm)) |
| Q1 2026 | [Obefazimod NDA/BLA submission](https://sec-api.dev/pdufa/obefazimod) | ABVX |  | scheduled | "These forward-looking statements include statements concerning the potential therapeutic benefit of obefazimod, the expected timing for completion of the Phase 3 ABTECT-UC maintenance trial and Phase 2b ENHANCE-CD induction trial of obefazimod and the availability and timing of results therefrom, the timing of regulatory filings including an NDA submission for obefazimod in UC, Abivax's expectations for regulatory approval and commercialization of obefazimod for UC, Abivax's cash runway, the timing for reporting Abivax's Q1 2026 financial results, Abivax's expectations of announcing of a new independent director, and other statements that are not historical fact." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000010/a6-kpressreleasefy2025fina.htm)) |
| Q2 2026 | [Abivax S.A. topline data readout](https://sec-api.dev/companies/abvx/catalysts) | ABVX |  | scheduled | "We expect to report top-line data from our Phase 3 ABTECT maintenance trial in late second quarter of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)) |
| April 28, 2026 | [Obefazimod primary completion](https://sec-api.dev/pdufa/obefazimod) | ABVX | Ulcerative Colitis | completed | "NCT05535946 (ABTECT - Maintenance): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-28 (ACTUAL); Lead Sponsor Abivax S.A.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05535946)) |
| June 1, 2026 | [Obefazimod topline data readout](https://sec-api.dev/pdufa/obefazimod) | ABVX |  | completed, positive | "Paris: FR0012333284 - ABVX / Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced positive topline results from the Phase 3 ABTECT maintenance trial evaluating obefazimod, its investigational oral, first-in-class miR-124 enhancer, in adults with moderately to severely active ulcerative colitis ("UC")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526252360/d98688dex991.htm)) |
| June 29, 2026 | [Obefazimod topline data readout](https://sec-api.dev/pdufa/obefazimod) | ABVX |  | completed, positive | "On June 29, 2026, we announced positive topline results from Part 2 of our Phase 3 ABTECT 44-week maintenance trial evaluating obefazimod, our potential first-in-class oral miR-124 enhancer, in moderate to severely active UC." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526294491/d111359d424b5.htm)) |
| 2H 2026 | [Abivax S.A. topline data readout](https://sec-api.dev/companies/abvx/catalysts) | ABVX |  | scheduled | "CD in the fourth quarter of 2024, with a planned top-line data read-out in the second half of 2026, to potentially demonstrate outcomes consistent with those observed in our Phase 2 clinical trials for moderately to severely active UC." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1956827/000195682725000010/abvx-20241231.htm)) |
| 2H 2026 | [Abivax S.A. topline data readout](https://sec-api.dev/companies/abvx/catalysts) | ABVX |  | scheduled | "We intend to announce Phase 2b induction trial top-line results in the second half of 2026 with the objective to demonstrate clinical response and tolerability profile consistent with that already observed in our clinical trials for" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1956827/000195682725000010/abvx-20241231.htm)) |
| September 10, 2026 | [Obefazimod topline data readout](https://sec-api.dev/pdufa/obefazimod) | ABVX | Ulcerative Colitis | completed | "NCT05507203 (ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-24 (ACTUAL); Lead Sponsor Abivax S.A.; Results First Posted 2026-09-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05507203?tab=results)) |
| September 10, 2026 | [Obefazimod topline data readout](https://sec-api.dev/pdufa/obefazimod) | ABVX | Ulcerative Colitis | completed | "NCT05507216 (ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-24 (ACTUAL); Lead Sponsor Abivax S.A.; Results First Posted 2026-09-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05507216?tab=results)) |
| Q4 2026 | [Obefazimod topline data readout](https://sec-api.dev/pdufa/obefazimod) | ABVX | Moderately to Severely Active Crohn Disease | scheduled | "Based on the positive clinical data generated in our UC trials, preclinical studies in dextran sulfate sodium ("DSS") mouse model which provide support for pursuing further development in CD, and underlying biological and mechanistic rationale, we also initiated a Phase 2b clinical trial in patients with CD in the fourth quarter of 2024, with a planned top-line induction data read-out in the fourth quarter of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)) |
| Q4 2026 | [Obefazimod NDA/BLA submission](https://sec-api.dev/pdufa/obefazimod) | ABVX |  | scheduled | "Fourth Quarter 2026 - Planned NDA submission for obefazimod in UC" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526288752/d110874dex991.htm)) |
| December 2026 | [Obefazimod primary completion](https://sec-api.dev/pdufa/obefazimod) | ABVX | Moderately to Severely Active Crohn Disease | scheduled | "NCT06456593 (Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Abivax S.A.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06456593)) |
| 2027 | [Obefazimod topline data readout](https://sec-api.dev/pdufa/obefazimod) | ABVX |  | scheduled | "Topline results of Phase 2b induction trial for Crohn's disease expected mid-year 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526252360/d98688dex991.htm)) |
| March 2028 | [ABX464 primary completion](https://sec-api.dev/pdufa/abx464) | ABVX | Ulcerative Colitis | scheduled | "NCT05177835 (Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Abivax S.A.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05177835)) |
| Mar to Jun 2028 | [ABX464 topline data readout](https://sec-api.dev/pdufa/abx464) | ABVX | Ulcerative Colitis | scheduled | "NCT05177835 (Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Abivax S.A.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05177835)) |

## Drugs

- [ABX464](https://sec-api.dev/pdufa/abx464): Ulcerative Colitis
- [Obefazimod](https://sec-api.dev/pdufa/obefazimod): chronic inflammatory diseases, today, crohns disease, crohn's disease, Ulcerative Colitis, Moderately to Severely Active Crohn Disease

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/abvx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ABVX catalysts: Abivax S.A. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/abvx/catalysts

```bibtex
@misc{secapidev_companies_abvx_catalysts_20261116,
  title        = {ABVX catalysts: Abivax S.A. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/abvx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_abvx_catalysts_20261116","title":"ABVX catalysts: Abivax S.A. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/abvx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
